Date Filed | Type | Description |
08/09/2018 |
SC 13G/A
| MORGAN STANLEY reports a 0% stake in Diadexus, Inc. |
02/13/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2017 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
04/29/2016 |
10-Q
| Quarterly Report for the period ended March 31, 2016 |
04/28/2016 |
8-K
| Quarterly results |
04/18/2016 |
8-K
| Form 8-K - Current report |
04/01/2016 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits |
03/29/2016 |
10-K
| Annual Report for the period ended December 31, 2015 |
03/28/2016 |
8-K
| Quarterly results |
03/17/2016 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
10/30/2015 |
10-Q
| Quarterly Report for the period ended September 30, 2015 |
10/26/2015 |
8-K
| Quarterly results |
09/08/2015 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities |
08/20/2015 |
8-K
| Regulation FD Disclosure |
08/13/2015 |
10-Q
| Quarterly Report for the period ended June 30, 2015 |
08/13/2015 |
8-K
| Quarterly results |
07/16/2015 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
07/16/2015 |
4
| Sperzel John J III (Director) has filed a Form 4 on Diadexus, Inc.
Txns:
| Granted 4,000 options to buy
@ $4.21, valued at
$16.8k
|
|
07/16/2015 |
4
| SULAT JAMES R (Director) has filed a Form 4 on Diadexus, Inc.
Txns:
| Granted 4,000 options to buy
@ $4.21, valued at
$16.8k
|
|
07/16/2015 |
4
| Hutt Pollard Elizabeth Ann (Director) has filed a Form 4 on Diadexus, Inc.
Txns:
| Granted 4,000 options to buy
@ $4.21, valued at
$16.8k
|
|
07/16/2015 |
4
| Drexler Karen (Director) has filed a Form 4 on Diadexus, Inc. |
07/02/2015 |
4
| RAFIELD LORI F PHD (CEO) has filed a Form 4 on Diadexus, Inc. |
07/02/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
07/01/2015 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
06/10/2015 |
8-K
| Submission of Matters to a Vote of Security Holders |
05/13/2015 |
10-Q
| Quarterly Report for the period ended March 31, 2015 |
05/12/2015 |
8-K
| Quarterly results |
04/30/2015 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/30/2015 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements |
04/22/2015 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
|
"Lori Rafield, Ph.D. Appointed Permanent CEO of Diadexus SOUTH SAN FRANCISCO, Calif., April 20, 2015 -- Diadexus, Inc. , a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced the appointment of Lori F. Rafield, Ph.D. as chief executive officer of the Company on a permanent basis, effective immediately. Dr. Rafield has continued to serve as chairman since 2010. She assumed the responsibility of interim executive chair in June 2014 and then was appointed interim chief executive officer in January 2015. “Lori has assembled a leadership team with deep operating experience and we are pleased she has agreed to lead this team as Diadexus' permanent chief executive officer,” said Karen Drexler, independent director of the b..." |
|
04/21/2015 |
4
| RAFIELD LORI F PHD (Interim CEO) has filed a Form 4 on diaDexus, Inc. |
04/17/2015 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
03/31/2015 |
4
| Hutt Pollard Elizabeth Ann (Director) has filed a Form 4 on diaDexus, Inc.
Txns:
| Granted 30,000 options to buy
@ $0.44, valued at
$13.2k
|
|
03/30/2015 |
4
| RAFIELD LORI F PHD (Interim CEO) has filed a Form 4 on diaDexus, Inc. |
|